Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Author’ response
Author’s reply
Authors' response
Authors#x2019; response
Book Received
Book Review
Book Reviews
Centenary Review Article
Clinical Image
Clinical Images
Commentary
Communicable Diseases - Original Articles
Correspondence
Correspondence, Letter to Editor
Correspondences
Correspondences & Authors’ Responses
Corrigendum
Critique
Current Issue
Editorial
Errata
Erratum
Health Technology Innovation
IAA CONSENSUS DOCUMENT
Innovations
Letter to Editor
Malnutrition & Other Health Issues - Original Articles
Media & News
Notice of Retraction
Obituary
Original Article
Original Articles
Perspective
Policy
Policy Document
Policy Guidelines
Policy, Review Article
Policy: Correspondence
Policy: Editorial
Policy: Mapping Review
Policy: Original Article
Policy: Perspective
Policy: Process Paper
Policy: Scoping Review
Policy: Special Report
Policy: Systematic Review
Policy: Viewpoint
Practice
Practice: Authors’ response
Practice: Book Review
Practice: Clinical Image
Practice: Commentary
Practice: Correspondence
Practice: Letter to Editor
Practice: Obituary
Practice: Original Article
Practice: Pages From History of Medicine
Practice: Perspective
Practice: Review Article
Practice: Short Note
Practice: Short Paper
Practice: Special Report
Practice: Student IJMR
Practice: Systematic Review
Pratice, Original Article
Pratice, Review Article
Pratice, Short Paper
Programme
Programme, Correspondence, Letter to Editor
Programme: Commentary
Programme: Correspondence
Programme: Editorial
Programme: Original Article
Programme: Originial Article
Programme: Perspective
Programme: Rapid Review
Programme: Review Article
Programme: Short Paper
Programme: Special Report
Programme: Status Paper
Programme: Systematic Review
Programme: Viewpoint
Protocol
Research Correspondence
Retraction
Review Article
Short Paper
Special Opinion Paper
Special Report
Special Section Nutrition & Food Security
Status Paper
Status Report
Strategy
Student IJMR
Systematic Article
Systematic Review
Systematic Review & Meta-Analysis
Viewpoint
White Paper
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Author’ response
Author’s reply
Authors' response
Authors#x2019; response
Book Received
Book Review
Book Reviews
Centenary Review Article
Clinical Image
Clinical Images
Commentary
Communicable Diseases - Original Articles
Correspondence
Correspondence, Letter to Editor
Correspondences
Correspondences & Authors’ Responses
Corrigendum
Critique
Current Issue
Editorial
Errata
Erratum
Health Technology Innovation
IAA CONSENSUS DOCUMENT
Innovations
Letter to Editor
Malnutrition & Other Health Issues - Original Articles
Media & News
Notice of Retraction
Obituary
Original Article
Original Articles
Perspective
Policy
Policy Document
Policy Guidelines
Policy, Review Article
Policy: Correspondence
Policy: Editorial
Policy: Mapping Review
Policy: Original Article
Policy: Perspective
Policy: Process Paper
Policy: Scoping Review
Policy: Special Report
Policy: Systematic Review
Policy: Viewpoint
Practice
Practice: Authors’ response
Practice: Book Review
Practice: Clinical Image
Practice: Commentary
Practice: Correspondence
Practice: Letter to Editor
Practice: Obituary
Practice: Original Article
Practice: Pages From History of Medicine
Practice: Perspective
Practice: Review Article
Practice: Short Note
Practice: Short Paper
Practice: Special Report
Practice: Student IJMR
Practice: Systematic Review
Pratice, Original Article
Pratice, Review Article
Pratice, Short Paper
Programme
Programme, Correspondence, Letter to Editor
Programme: Commentary
Programme: Correspondence
Programme: Editorial
Programme: Original Article
Programme: Originial Article
Programme: Perspective
Programme: Rapid Review
Programme: Review Article
Programme: Short Paper
Programme: Special Report
Programme: Status Paper
Programme: Systematic Review
Programme: Viewpoint
Protocol
Research Correspondence
Retraction
Review Article
Short Paper
Special Opinion Paper
Special Report
Special Section Nutrition & Food Security
Status Paper
Status Report
Strategy
Student IJMR
Systematic Article
Systematic Review
Systematic Review & Meta-Analysis
Viewpoint
White Paper
View/Download PDF

Translate this page into:

Practice: Original Article
158 (
2
); 161-174
doi:
10.4103/ijmr.ijmr_3282_21

Normative data for paediatric lymphocyte subsets: A pilot study from western India

Department of Pediatric Immunology & Leukocyte Biology, Indian Council of Medical Research - National Institute of Immunohaematology, KEM Hospital, Mumbai, Maharashtra, India
Division of Immunology, Bai Jerbai Wadia Hospital for Children, Mumbai, Maharashtra, India
Department of Obstetrics & Gynaecology, Nowrosjee Wadia Maternity Hospital, Mumbai, Maharashtra, India
Department of Paediatrics, Kashyap Nursing Home, Mumbai, Maharashtra, India
Department of Biosciences & Bioengineering, Indian Institute of Technology, Guwahati, Assam, India

For correspondence: Dr Manisha Madkaikar, Indian Council of Medical Research - National Institute of Immunohaematology, 13th-Floor New Multistorey Building, KEM Hospital, Parel, Mumbai 400 012, Maharashtra, India e-mail: madkaikarmanisha@gmail.com

Licence
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Disclaimer:
This article was originally published by Wolters Kluwer - Medknow and was migrated to Scientific Scholar after the change of Publisher.

Abstract

Background & objectives:

Accurate diagnosis of immunodeficiencies requires a critical comparison of values with age-matched controls. In India, the existing reference values for rare lymphocyte subsets are currently not available and we rely on the data originating from other countries for the interpretation of the results. Furthermore, there is limited information on normal variation for these rare-subset parameters in Indian children. So, this study aimed to establish normative values for clinically important lymphocyte subsets in Indian children at different age groups.

Methods:

148 children aged ≥16 yr were enrolled in this study. The study population included 61 per cent males and 39 per cent females and was divided into the following groups: cord blood (n=18), 0-6 months (n=9), 6-12 months (n=13), 1-2 yr (n=19), 2-5 yr (n=27), 5-10 yr (n=25) and 10-16 yr (n=37). The absolute and relative percentage of lymphocytes, T, B, natural killer cell, along with activated, naïve and memory subsets, was determined by flow cytometry.

Results:

Median values and the 10th and 90th percentiles were obtained for 34 lymphocyte sub-populations. The T and B naïve compartments showed a decreasing trend, whereas memory cells showed an increase with age. The activated T cell subset shows an increasing pattern up to one year and then declines gradually. Double negative T cells are relatively stable. TCRgd+T cell percentage increases with age.

Interpretation & conclusions:

This single-centre pilot study provides preliminary data that justifies the need for future large-scale multi centric studies to generate a reference range for interpreting extended immunophenotyping profiles in the paediatric age group, making it possible for clinicians to assess the immunological status in inborn errors of immunity, infectious and autoimmune diseases.

Keywords

Children
flow cytometry
lymphocyte subset
pilot study
primary immunodeficiency

Flow cytometry functions as a rapid and efficacious technique for quantifying different leukocyte subsets, predominantly lymphocytes, along with the evaluation of expressed proteins. This method holds paramount significance in the diagnosis of inborn errors of immunity (IEI), as well as the assessment of immunological status in infectious and autoimmune diseases1. The age of presentation varies from infancy to late adulthood2. The patients with IEI present with recurrent infections or immune dysregulation2. There has been an exponential increase in the diagnosis of novel IEI in the last decade, leading to a better prognosis and management of these cases2. One of the initial steps in the diagnostic workup for patients with IEI includes peripheral blood immunophenotyping. Still, reliable age-wise reference values for rare lymphocyte subpopulations are limited3,4.

Clinical decision-making of immune deficiencies relies on measurable deviations of the patient’s values from normal, and this mainly depends on the availability of the reference ranges4. Flow cytometric age-related reference ranges of major lymphocyte subsets are available from various ethnicities5-7. Sub-characterization of these subsets is usually not performed as a part of routine standard phenotyping despite available knowledge regarding associations between lymphocyte subsets with certain disease states8. With the advent of a multicolour flow cytometer and a wide range of fluorescent-conjugated antibodies, sub-characterization of cells has become easier.

While data on the prevalence of IEI are lacking in India, it is speculated that India may have nearly one million patients with IEI9,10. Although reference ranges for lymphocytes are available for healthy adults11-13 and children14, there is a paucity of data for the rare subsets in the Indian population. This study presents paediatric age-matched reference values for lymphocyte subsets and some T and B cell subpopulations using the dual-platform method, which are essential for cell maturation and activations (both percentage and absolute count). This will provide a guideline for interpreting the immunophenotype as part of the diagnostic process for IEI and other immune diseases such as HIV and for immune monitoring in infectious diseases such as coronavirus disease (COVID)-19 and other autoimmune diseases.

Material & Methods

This pilot study was undertaken at the department of Paediatric Immunology and Leukocyte Biology, ICMR-National Institute of Immunohaematology (NIIH), Mumbai, India. The study was approved by the Institutional Ethics Committee of ICMR-NIIH, B J Wadia hospital for children and Nowrosjee Wadia Maternity Hospital.

Study population: A total of 148 healthy children, 0-16 years of age were recruited for the study between January 2018 to February 2021 (details in

Supplementary Fig. 1
). Cord blood (CB) samples from full-term healthy neonates and leftover ethylene diamine tetraacetic acid (EDTA) blood from healthy children, who underwent venipuncture for screening before benign surgical procedures without any evidence of infectious, immunologic or haematologic disorders, were used. For participants aged 10-16 yr, the sample was also collected through voluntary blood sampling at schools after procuring a written informed consent from their parents. Their overall health status was evaluated by detailed clinical history and physical examination.

Exclusion criteria were a history of previous sibling death, fever, rash, diarrhoea, recurrent cold, cough, blood transfusion and any medicine or steroids during the past one month or any history of chronic diseases such as tuberculosis, asthma, diabetes and atopic dermatitis.

For the CB sample, babies with normal birth weight and full term delivery were included. Family history of early sibling death, consanguinity of parents, newborn factors such as baby fever, jaundice, anaemia, low APGAR at birth and signs of sepsis were excluded from the study. Maternal factors such as illness in the mother during the last trimester, fever, history of diabetes, hypothyroidism, toxaemia, preterm, gestation prolonged rupture of membrane and recent illness in parents were excluded. The study population was 61 per cent males and 39 per cent females and was divided age wise into groups: CB (n=18), 0-6 months (n=9), 6-12 months (n=13), 1-2 yr (n=19), 2-5 yr (n=27), 5-10 yr (n=25) and10-16 yr (n=37).

Sample preparation: Whole blood (3 ml) was collected in EDTA vials by venipuncture and processed within 24-36 h of collection. The absolute lymphocyte number was determined from whole blood using Sysmex Haematology analyzer XS-800i (Sysmex Co., Cobe, Japan). The whole blood sample was used for flow cytometry analysis.

Immunophenotyping/multicolour staining & analysis: Immunohenotyping was carried out on 10-color Navios Ex (Beckman Coulter, FL,USA) flowcytometer or 13- colour Dxflex (Beckman Coulter) flowcytometer. The acquisition was run until 50,000 CD3+T cells and 10,000 CD19+B cells were detected. Kaluza analysis software V2.1 (Beckman Coulter) was used for data analysis.

Multicolor flow cytometry was utilized for the identification of B, T, and natural killer (NK) cells along with their distinct subsets (details in Supplementary Table I). Singlet gating strategy was applied to eliminate aggregates, and scatter gates were defined specifically for lymphocytes. The lymphocyte population was discerned from the sample by employing forward scatter and side scatter (SS) gating. Furthermore, this lymphocyte population, characterized by low forward and SS values, was evaluated for its purity through CD45 positivity analysis. Immunophenotype markers identified subsequent lymphocyte subpopulations. At certain fluorochrome, dual markers were combined due to their mutually exclusive presentation, i.e. one B cell and another T cell (e.g. CD8 with IgD and CD19 with TCRgd), while CD16 and CD56 were used to detect NK cells1.

Supplementary Table I Cell surface markers used for analyzing peripheral blood lymphocyte subsets
Subset Anchor marker CD subset measured
T cell CD45 CD3+
NK cell CD45 CD3−CD16+CD56+
B cell CD45 CD3−CD19+
Th cell CD45 CD3+CD4+
Tc cell CD45 CD3+CD8+
Th Naïve cell (CD27) CD4 CD27+CD45RA+
Th RTE CD4 CD31+CD45RA+
CM Th cell (CD27) CD4 CD27+CD45RA−
EM Th cell (CD27) CD4 CD27−CD45RA−
TEMRA Th cell (CD27) CD4 CD27−CD45RA+
Tc Naïve cell (CD27) CD8 CD27+CD45RA+
CM Tc cell (CD27) CD8 CD27+CD45RA−
EM Tc cell (CD27) CD8 CD27−CD45RA−
TEMRA Tc cell (CD27) CD8 CD27−CD45RA+
Tc RTE CD8 CD31+CD45RA+
RTE on Th Naïve CD4 CD31+CD45RA+CD62L+
RTE on Tc Naïve CD8 CD31+CD45RA+CD62L+
Total memory B cell CD19 CD27+
Class switch memory B cell CD19 CD27+IgM−IgD−
Unswitched memory B cell CD19 CD27+IgM+IgD+
IgM only memory B cell CD19 CD27+IgM+IgD−
Naïve B cells CD19 CD27−IgD+
Pre-GC B cells CD19 CD27−IgD+IgM+
Double negative B cell CD19 CD27−IGD−
DNT on Lymphs CD45 CD3+CD4−CD8−
DPT on Lymphs CD45 CD3+CD4+CD8+
DNT ab+T CD3 CD3+CD4−CD8−TCRgd−/TCRab+
DNT gd+T CD3 CD3+CD4−CD8−TCRgd+
gd- T/ab+T CD3 TCRgd−
gd+T CD3 TCRgd+
NKT CD45 CD3+CD16+CD56+
HLADR+Th cell CD3 CD4+HLADR+
HLADR+Tc cell CD3 CD8+HLADR+
HLADR+T cell CD3 HLADR+
HLADR+NK cell CD16/CD56 HLADR+
HLADR+45RA OF DNTgd-T CD3 CD3+CD4−CD8−TCRgd−HLADR+CD45RA+
Th Naïve cell (CD62L) CD4 CD62L+CD45RA+
CM Th cell (CD62L) CD4 CD62L+CD45RA−
EM Th cell (CD62L) CD4 CD62L−CD45RA−
TEMRA Th cell (CD62L) CD4 CD62L−CD45RA+
Tc Naïve cell (CD62L) CD8 CD62L+CD45RA+
CM Tc cell (CD62L) CD8 CD62L+CD45RA−
EM Tc cell (CD62L) CD8 CD62L−CD45RA−
TEMRA Tc cell (CD62L) CD8 CD62L−CD45RA+
gd+T of Lymphs CD45 CD3+TCRgd+

TEMRA, terminally differentiated effector memory re-expressing CD45RA; CM, central memory; EM, effector memory; DNT, double negative T; NK, natural killer; gd, gamma delta; Tc, T cytotoxic; Th, T helper; HLADR, human leukocyte antigen DR

To assess the cell composition, the wash-stain-lyse-wash method was used15. Briefly, 200 μl of whole blood was washed twice with phosphate-buffered saline (PBS). The cells were incubated in dark for 20 min at room temperature with a mixture of optimally titrated monoclonal antibodies (details in Supplementary Table II), followed by lysis using Optilyse C™ (Beckman coulter) for 10 min. After washing once with PBS, the cells were acquired on DxFlex or Navios Ex Beckman Coulter) flow cytometer and analyzed using Kaluza v2.1 data analysis software (Beckman Coulter). The determination of absolute subset cell counts was achieved through a dual platform approach involving the multiplication of the subset proportion acquired via flow cytometry and the absolute lymphocyte count as assessed using a 5 part haematology analyzer (Sysmex Co.,Cobe, Japan).

Supplementary Table II Monoclonal antibody used for extended immunophenotyping
Cell type Antibody Fluorochrome Clone Maker
General lymphocyte population CD45 APCH7 J3-119 BC
CD16+CD56 PE 3G8+N901 BD+BC
CD19 PC7 2D1 BD
CD3 APC UCHT1 BC
T cell subpopulation CD4 PERCP Cy5.5 SK-3 BD
CD8 FITC SK-1 BC
CD27 ECD IA4CD27 BD
TCRgd PC7 IMMU-510 BC
HLADR PACIFIC BLUE IMMU-357 BC
CD45RA BV510 H100 BD
B cell subpopulation IgD FITC IA6-2 BIOLEGEND
CD27 ECD IA4CD27 BC
IgM PERCP Cy5.5 MHM-88 BIOLEGEND
RTE CD31 FITC 5.6E. BC
CD45RA PE ALB11 BC
CD3 ECD UCHT1 BC
CD4 PC7 SFCI12T4D11 BC
CD62L APC DREG-56 BD
CD8 APC750 B9.11 BC

RTE, recent thymic emigrants; HLADR, human leukocyte antigen DR

Quality control: Machine daily quality check was ensured using quality control beads for DxFlex (Beckman coulter) using Cytoflex beads and Navios Ex (Beckman Coulter) using the Flow-Check fluorospheres. Quality control was run according to the manufacturer’s instructions and standard laboratory protocol. Levey-Jennings chart was prepared using Kaluza analysis software and half peak CV for all parameters were plotted, which was within the acceptable limits (±2 standard deviation), ensuring reliability and accuracy of the machine.

Statistical analysis: The number of participants in different age groups varied from nine to 37 (n=148). Data analysis used the GraphPad Prism software, version 9.1 (GraphPad Prism, CA, USA), RStudio- V1.4 (R Core Team, Vienna, Austria) and Microsoft Excel (Microsoft Office 2010, USA). For each cell population, the normal range was defined based on the median, as well as the 10th and 90th percentiles of the cell frequencies. Each variable was analysed in both absolute number as well as percentage. Differences between study groups (age) were assessed by the Kruskal-Wallis test followed by Dunn’s multivariate comparison. The P<0.05 was considered significant. An unpaired t test was used to compare subsets of helper and cytotoxic T (Tc) cells to test the difference between CD62L and CD27.

Results

An immunophenotyping platform was established to explore the variation in immune system composition. This platform utilizes flow cytometry to quantitatively assess over 34 discrete immunological attributes, with specific emphasis on subsets within the adaptive immune system The median along with 10th-90th percentiles of absolute and relative size for different age groups are shown in Tables I and II, respectively. Significant variation was observed among different age groups. Figures 1 and 2 show the gating strategy for lymphocyte sub-populations. Using this gating strategy, age-related reference values for relative percentage and absolute lymphocyte subset counts of 148 healthy individuals among seven different age groups were calculated. The values are represented as box plots with median, p10, p25, p75 and p90 percentile in Figures 3 and 4.

Table I Median and 10-90th percentile of lymphocyte and its subpopulation absolute number (/ul blood) by age group
Absolute count/age CB (n=18) 0-6 months (n=9) 6-12 months (n=13) 1-2 yr (n=19) 2-5 yr (n=27) 5-10 yr (n=25) 10-16 yr (n=37)
Lymphocytes*** 3627 6013y,x 6029u 5210r,t,q 4226o 3108 3087
2809-5917 3744-8637 3537-8294 3182-7410 3048-6752 2258-4781 2038-4113
NK cell 250 338 297 342 325 258 238
69-1412 220-779 84-1237 144-565 130-636 90-679 110-437
T cell*** 2423 4321 3952u,t 3642r,q 2744o 2300 2291
1889-4764 2617-5380 2252-5788 2105-5460 2087-4899 1639-3388 1390-3008
Th cell*** 1637δ,% 2802y,x 2274u,t 2090r,q 1463o 1109 1168
1060-3558 1336-3327 1207-4013 1154-3460 1001-2535 805-1855 659-1547
Tc cell*** 707#,$,^ 1010 1315t 1185q 1057 856 841
451-1346 618-1778 548-1930 781-1692 562-1809 508-1257 471-1242
Th Naive cell (CD27)*** 1445δ,% 2619>,y,x 1797u,t 1552r,q 1057 825 644
1001-3329 993-3086 758-2992 816-2509 711-1844 416-1462 325-1208
Th RTE*** 1297δ,% 1905y,x 1625u,t 1375r,q 806o 570 459
842-2911 766-2563 593-2977 701-2388 522-1456 342-1126 227-860
CM Th cell (CD27)*** 128#,$,^,δ,% 285 293 351 300 283 337
57-290 195-363 196-605 195-753 215-580 151-420 172-511
EM Th cell (CD27)*** 1@,$,^,δ,% 35 25t 37q 38o 49 76
0-4 7-84 11-95 9-126 17-87 23-148 49-155
TEMRA Th cell (CD27)*** 0$,^,δ,% 14x 9t 8 4 39 21
0-1 1-56 1-157 1-218 1-29 4-131 3-103
Tc Naive cell (CD27)*** 624 869x 773 757q 790p,o 537 414
418-1206 434-1135 410-1223 437-1185 456-1293 306-844 244-829
Tc RTE*** 658 816 899t 779q 753o 615.5 471
435-1229 391-1088 447-1379 516-1289 422-1265 312-870 273-855
CM Tc cell (CD27)*** 58@,$,^,δ,% 167 133 161 110 122 142
22-115 73-320 38-417 46-352 53-349 40-242 51-245
EM Tc cell (CD27)*** 0@,#,$,^,δ,% 31 23 19 12 16 26
0-1 1-180 1-223 3-76 2-114 5-117 9-103
TEMRA Tc cell (CD27)*** 0@,#,$,^,δ,% 72 112 133 65 131 108
0-4 1-346 3-962 8-306 5-424 21-301 25-378
RTE on Th Naive*** 1251δ,% 1473y,x 1564u,t 1277r,q 749o 495 445
822-2720 776-2186 582-2605 676-1879 476-1314 281.5-1022 204-812
RTE on Tc Naive*** 646% 744x 686t 703q 698p 468.5 385
412-1136 345-908 326-1122 438-1126 379-1080 273-782 186-596
B cell*** 628@,#,$ 1912y,x 1405u,t 1124r,q 815p,o 440 556
255-972 240-2636 715-2531 718-2007 510-1662 286-924 273-813
Total memory B cell*** 15#,$,^,δ,% 81>,z 134 170q 168 106 116
7-38 13-139 43-406 66-267 64-253 46-225 26-175
Class switch memory B cell*** 0#,$,^,δ,% 10 37 78 51 41 53
0-1 2-70 12-331 25-160 25-106 15-90 11-113
Unswitched memory B cell*** 14^ 39 33t 38q 35o 23 13
7-32 06-69 13-161 6-99 7-93 5-69 02-31
IgM only memory B cell*** 0#,$,^,δ,% 4 6 6 5 3 5
0-0 0-5 3-17 2-21 01-19 1-11 1-17
Naive B cells*** 595 1701y,x 1254u,t 963r,q 659o 314 391
240-923 222-2512 638-2137 547-1811 342-1428 193-764 195-658
Pre-GC B cells*** 575δ,% 786y,x 542u,t 542 r,q 379o 170 75
238-903 132-2464 410-1847 69-906 98-908 52-554 23-407
Double negative B cell 0 1 1 1 1 1 1
0-1 0-2 0-2 0-1 0-1 0-2 0-1
CD4-CD8-DNT on Lymphs*** 72#,$,^,δ,% 129 215 187 232 148 165
30-168 77-355 68-288 116-356 112-402 111-406 81-375
CD4+CD8+DPT on Lymphs*** 45 80y,x 53 35 37 24 25
15-113 28-461 11-146 17-114 13-116 15-57 13-80
DNT gd-ab+T*** 26#,$,^ 51 59 88r,q 85p,o 45 40
14-56 17-149 30-105 42-137 48-125 30-90 26-65
DNT gd+T*** 74.5#,$,^,δ,% 121 253 209 234 182 165
25-167 76-205 66-441 128-348 126-470 84-467 67-359
TCR gd-ab+T*** 2370 4143y,x 3617u,t 3204r,q 2556o 2086 2004
1819-4662 2226-4835 2157-5516 1946-4883 1875-4537 1484-2923 1297-2694
TCR gd+T*** 68@,#,$,^,δ,% 191 246 206 241 189 189
26-174 119-545 73-558 135-340 133-406 97-390 64-353
NKT 259 338 444 359 380o 361 224
141-622 145-841 134-1328 173-924 89-1180 203-778 71-516
HLADR+Th cellv 7@,#,$,^,δ,% 45 53 35 26.5 31 38.5
2-24 32-120 22-76 16-117 17-97 17-64 13-67
HLADR+Tc cell*** 3@,#,$,^,δ,% 142 101 108 41.5 50 50
1-8 13-295 14-263 21-209 14-195 20-124 9-139
HLADR+T cell*** 14.5@,#,$,^,δ,% 281 194 182 85 90 106
6-34 62-585 57-403 48-391 38-287 55-201 38-200
HLADR+NK cell* 19@,$ 66 39 53 39 36 30
3-450 19-199 22-89 20-102 16-118 13-92 13-50
HLADR+45RA of DNTgd-T*** 1#,$,^, 4 4 4 4 2 2
0-3 0-6 02-13 0-7 0-7 1-5 1-3
Th Naive cell (CD62L)*** 1503δ,% 2177z,y,x 1811u,t 1578r,q 957o 632 564 ***
944-3371 875-2896 793-3181 791-2812 627-1570 388-1268 285-995
CM Th cell (CD62L)*** 114@,#,$,^,δ,% 337 233 303 192 199 268
28-178 50-465 100-468 146-494 104-477 83-342 152-447
EM Th cell (CD62L)*** 40.5#,$,^,δ,% 129 142 154 212 153 201
12-102 0-474 28-312 85-341 66-337 74-256 77-314
TEMRA Th cell (CD62L)* 56.5 25 49 66 30 72.5n 17
14-146 2-418 11-381 7-460 1-324 8-236 7-72
Tc Naive cell (CD62L) 656% 823x 754t 821q 791o 633.5 470
419-1146 369-1169 374-1307 506-1243 405-1233 301-991 230-653
CM Tc cell (CD62L) 28$,^,% 78 50 92 97 46 93
6-79 29-393 17-236 28-309 24-238 10-253 18-218
EM Tc cell (CD62L) 2,#,$,^,δ,% 24 60 63 34 101 69
0-13 7-198 11-364 12-269 12-327 11-297 22-242
TEMRA Tc cell (CD62L) 12#,$,% 52 84 113 76 29 136
0-113 8-279 18-708 27-284 6-362 6-188 10-355

P*<0.05,**<0.01,***<0.001. Difference in intergroup are represented as: @CB vs. 0-6 months; #CB vs. 6-12 months; $CB vs. 1-2 yr; ^CB vs. 2-5 yr; δCB vs. 5-10 yr; %CB vs. 10-16 yr; ’’0-6 months vs. 6-12 months; >0-6 months vs. 1-2 yr; z0-6 months vs. 2-5 yr; y0-6 months vs. 5-10 yr; x0-6 months vs. 10-16 yr; w6-12 months vs. 1-2 yr; v6-12 months vs. 2-5 yr; u6-12 months vs. 5-10 yr; t6-12 months vs. 10-16 yr; s1-2 yr vs. 2-5 yr; r1-2 yr vs. 5-10 yr; q1-2 yr vs. 10-16 yr; p2-5 yr vs. 5-10 yr; o2-5 yr vs. 10-16 yr; n5-10 yr vs. 10-16 yr. RTE, recent thymic emigrant; CM, central memory; EM, effector memory; TEMRA, terminally differentiated effector memory re-expressing CD45RA+; Tc, T cytotoxic; Th, T helper; CB, cord blood

Table II Median and 10-90th percentile of lymphocyte and its subpopulation relative percentage by age group
Percentage/age CB (n=18) 0-6 months (n=9) 6-12 months (n=13) 1-2 yr (n=19) 2-5 yr (n=27) 5-10 yr (n=25) 10-16 yr (n=37)
Lymphocytesa*** 39.3@,#,$ 62.5z,y,x 58.8u,t 57s,r,q 43.4 38.7 39
24.2-48.4 41.6-73 39.1-69.4 49.8-64.1 31.3-61. 24.5-49.0 27.5-48.2
NK cellb 6.3 5.6 5.2 6.7 7.2 8.8 8.3
2.7-26.0 3.9-9.0 2.3-20.8 2.98-11.2 2.92-14.0 3.05-20.4 4.6-12.1
T cellb* 68.4 62.3 63.7 65.3 68.6 72.7 70.9
55.9-85.7 52.1-86.3 49.5-75.9 57.7-74.3 57.1-75.5 60.5-78.8 61.4-79.6
Th cellb*** 48.8^,δ,% 39.3 42.6 37.4 34.5 36.5 35.1
31.5-61.3 35.3-63.5 21.0-51.2 31.5-49.4 28.7-42.2 27.0-47.1 27.8-44.6
Tc cellb*** 17.8^,δ,% 18.4z,y,x 19.3t 23.3q 26.9 26.5 27.3
12.7-27.8 13.1-22.3 13.7-28.5 17.8-26 17.6-34.8 19.2-36.5 20.7-36.7
Th Naïve cell (CD27)c*** 93.3$,^,δ,% 86.96y,x 83.9t 78q 75.7 71 61.6
84.5-96.6 74.3-92.8 57.2-90.3 62.3-86.8 63.9-81.0 51.7-82.2 39.9-76.8
Th RTEc*** 76.7^,δ,% 68x 71.1t 61.4q 58.1o 52.3 43.6
65.1-85.1 57.4-78.1 49.1-77.2 48.9-72 43.9-67.7 42.2-64.2 31.7-59.8
CM Th cell (CD27)c*** 6.5$,^,δ,% 11.4z,y,x 13.6t 19 20.7 24.3 28.8
3.03-15.2 6.8-19.8 8.9-26.8 11.7-27.3 17.4-29.2 15.2-35.8 17.2-49.2
EM Th cell (CD27)c*** 0.03$,^,δ,% 1.2x 1.1t 1.7q 2.7o 3.7 6.7
0.01-0.2 0.2-3.6 0.4-6.9 0.4-8.0 1.2-5.4 1.9-13.9 4.1-15.3
TEMRA Th cell (CD27)*** 0@,#,$,^,δ,% 0.44 0.37 0.43 0.27p,o 2.7 2.14
0-0.1 0.02-2.4 0.02-11.5 0.06-10.6 0.05-2.3 0.2-11.4 0.2-6.9
Tc Naïve cell (CD27)d*** 91.1#,$,^,δ,% 70.3 71.5 66.7 76.4 66.2 57.5
87.1-96.9 60.4-92.7 35.2-91.7 48.5-88.9 53.7-90.9 43.2-77 36.4-80.6
Tc RTEd*** 94.9#,$,^ 70.96 71.8 66.7 74.5o 68.0 63.3
90.2-98.3 54.4-94.7 40.5-89.0 50.7-81.3 56.4-88.5 52.7-75.2 43.4-77.5
CM Tc cell (CD27)d* 9.0$,δ,% 14.6 10.5 16.2 12.7 14.9 18.34
3.1-13.3 7.1-26.2 6.6-29.9 4.7-31.6 4.20-22.8 4.9-28.1 9.8-30.4
EM Tc cell (CD27)d*** 0.01@,#,$,^,δ,% 2.7 1.5 1.6 1.2 1.9 4.1
0-0.2 0.1-11.7 0.1-10.8 0.3-7.9 0.3-8.6 0.5-12.8 1-9.2
TEMRA Tc cell (CD27)d*** 0.04#,$,^,*,% 7.5 12.0 12.6 5.9 13.8 17
0-0.7 0.1-19.5 0.2-47.1 1.10-26.7 0.8-30.1 3.0-36.5 3.1-35.7
RTE on Th Naïvec*** 71.2^,δ,% 60.2x 64.5u,t 58.9r,q 50.8 45.1 44.9
58.6-78.9 50.5-69.6 48.2-73.3 45.4-68.9 39.9-63.3 30.7-57.4 30.3-57.1
RTE on Tc Naïved*** 92.7@,#,$,^,δ,% 59.2 60.4 59.1 65.5o 58.3 47.32
83.8-96.1 49.5-79.8 26.9-84.1 38.2-78.4 43.7-80.4 35.7-68.6 32.1-66.2
B cellb*** 14.2@,$ 25.5y 23.3u 23.8r,q 21.6 16.6 17.9
8.1-28.4 4.6-35.9 12.4-37.8 16-36.9 12.3-34.1 10.5-26.2 10.7-26.3
Total memory B celle*** 2.5$,^,δ,% 5.3z,y,x 10.1u,t 14.3 16.6 25.1 19.4
1.7-5.4 1.3-16.8 3.8-19.6 7.3-21.8 8.7-30.0 10.6-35.2 7.2-33.7
Class switch memory B celle*** 0.03$,^,δ,% 0.9y,x 3.2t 6 5.9 8.9 9.8
0-0.2 0.1-9.05 0.89-16 2.96-9.7 3.8-10.7 4.1-15.1 3.8-7.5
Unswitched memory B celle* 2.3 2.4 2.5 2.7 5 4.8 2.6
1.5-4.96 0.36-7.34 0.9-8.99 0.6-9 1.0-10.15 0.9-14.94 0.7-6.4
IgM only memory B celle*** 0.02#,$,^,δ,% 0.19x 0.42 0.49 0.68 0.53 1.04
0-0.06 0-0.61 0.23-1.13 0.12-1.9 0.09-1.93 0.12-2.42 0.16-3.06
Naïve B cellse*** 94.7$,^,δ,% 92.7z,y,x 86.8u,t 82.4 79.7 70.4 75.9
92.6-96.4 79.9-96.6 74.1-92.7 73.6-90.2 67.1-88 59.8-82.9 59.8-89.6
Pre-GC B cellse*** 92.6#,$,^,δ,% 71.2x 51.4t 49.4 47.5 32.3 14.9
88.2-96.0 16.5-93.5 28.6-82.8 6.6-80.9 12.9-75.2 11.1-74.6 4.4-71.3
Double negative B celle*** 1.44δ,% 2.04 3.28 2.69 2.7 4.21 4.54
0.7-3.99 0.99-5.44 0.63-7.27 1.02-7.07 1.01-4.60 1.3-8.3 1.6-8.3
DNT on Lymphsb 1.7#,$,^,δ,% 2.1z,y,x 3v,u,t 3.8 5.35 5.31 5.26
0.91-3.37 1.02-9.47 1.5-4.5 3.3-5.6 3.1-8.2 3.3-9.9 3.1-10.9
DPT on Lymphsb 1.15 1.67 1.06 0.81 0.85 0.72 0.79
0.44-3.16 0.54-5.34 0.23-2.83 0.31-2.01 0.34-2.42 0.498-1.766 0.43-2.38
DNTgd-ab+Tf*** 0.68$,^,δ,% 0.88>,z 1.15v 1.72 1.85o 1.45 1.32
0.44-1.44 0.24-1.85 0.57-1.62 0.85-2.4 1.19-2.7 1.13-2.27 0.95-2.02
DNT gd+Tf*** 1.68$,^,δ,% 2.36z,y,x 3.54 3.93 5.77 5.66 5.27
0.65-3.14 1.4-12.01 1.58-6.82 2.82-8.03 2.86-9.73 2.88-12.45 2.45-10.86
TCRgd-ab+Tf*** 96.9$,^,δ,% 95.2 94 93.9 90.8 91.5 90.1
94.9-98.7 85.0-97.4 83.5-97.2 88.5-95.1 86.2-95.3 84.99-96.3 83.8-95.8
TCRgd+Tf*** 2.6#,$,^,δ,% 4.8 5.3 6 8 8.5 9.1
0.9-4.0 2.6-14.6 3.0-15.8 4.3-11.6 4.6-13.3 3.7-14.9 3.6-13.9
NKTb 7.1 6 7.6 7.6 10 11.2 7.4
4.2-14.1 2.8-10.4 2.2-26 3.3-19.1 2.5-21.8 6.6-27 2.2-19.3
HLADR+Th cellc*** 0.3@,#,$,^,δ,% 2 2.3 1.6 1.8 2.2 3.8
0.2-1.5 1.2-5 0.7-5.7 0.8-7.5 1.2-7.3 1.3-6.7 1.4-5.9
HLADR+Tc celld*** 0.45@,#,$,^,δ,% 14.3 7.2 7.1 3.5 5.2 6.4
0.2-1 1.2-19.3 2-16.2 1.9-22.1 1.6-17.0 2.8-16.8 2.3-18.7
HLADR+T cellf*** 0.49@,#,$,^,δ,% 6.35 4.9 3.95 2.6 3.5 4.5
0.3-1.4 1.4-10.9 1.4-10.1 1.3-14.3 1.4-8.1 2.1-10.0 2.1-10.2
HLADR+NK cellg 6.4@,$,^,δ,% 22.2 15.2 13.7 13.4 13.8 12.9
2.2-20.5 4.3-38.6 4.6-44 5.8-32.1 7.1-21.5 6.8-29.7 7.7-32.8
HLADR+45RA OF DNTgd-Th 3 6.2 7.6 3.8 4.6 3.9 4.2
0.4-10.6 2.6-10.9 2.1-14.2 0.9-7.8 0.5-9.3 1.4-7.9 1.2-12.1
Th Naïve cell (CD62L)c*** 88.3$,^,δ,% 80.8y,x 78.0u,t 71.4q 65o 54.5 55.2
80-95.5 65.5-87.1 64.7-83.7 59.5-82.8 54.8-81.3 41.8-79.7 33.8-70.7
CM Th cell (CD62L)c*** 5.7$,^,δ,% 14.3x 11.8t 14.3q 15.4o 17.9 25
1.7-11.7 2.1-19.4 3.5-19.8 7.6-22.2 6.3-23.1 7.4-32.3 16-33.1
EM Th cell (CD62L)c*** 2.4^,*,% 4.6y,x 7.6u,t 7.9q 12.5 14.9 17.5
0.3-5.3 0-20.1 1.20-10.8 2.9-15.9 4.9-18.7 5.2-22.9 9.2-30.6
TEMRA Th cell (CD62L)c* 3.2 1.1 3.2 2.9 2.2 6.7n 1.7
0.9-6.9 0.1-13.5 0.6-11.2 0.6-16.6 0.1-17.9 0.9-20.8 0.7-8.06
Tc Naïve cell (CD62L)d*** 93.8@,#,$,^,*,% 67.3 62 70.3 74.8o 71.2n 53.4
84.5-96.8 59.7-85.1 31.9-86.1 44.8-88.1 53.7-85.8 45.5-87 37-72.9
CM Tc cell (CD62L)d** 3.4^,% 8.2 4.5 7.7 8.2 5.1 7
1.1-8.1 3.0-28 1.2-15.3 2.9-24.8 2.1-19.7 1.1-29.6 3.0-29.7
EM Tc cell (CD62L)d*** 0.3#,$,^,*,% 2 5.2 6.5 3.3 11.9 11.5
0-1.6 0.7-29.7 1.3-25.8 0.95-22.6 1.2-21.3 1.3-29.1 2.3-26.5
TEMRA Tc cell (CD62L)d*** 2#,*,% 5.5 8.8 9.7 5.5o 3.6n 20.2
0-9.3 0.6-29.4 1.8-57.3 1.9-26.5 0.63-24.9 0.7-22.7 2.7-37.2
gd+T of Lymphsb*** 2^,*,% 3 4 4 6 6 6
0.9-3.1 2-10 1.4-8.4 3-5.4 3-9 2.6-10.4 2.8-10.2
CD4/CD8 ratio*** 2.49^,*,% 2.74z,y,x 2 2 1 1 1
1.1-3.8 2-4 1-3.6 1-3 1-2 1-2.4 1-2

P*<0.05, **<0.01, ***<0.001. Difference in intergroup are represented as: @CB vs. 0-6 months; #CB vs. 6-12 months; $CB vs. 1-2 yr; ^CB vs. 2-5 yr; δCB vs. 5-10 yr; %CB vs. 10-16 yr; ’’0-6 months vs. 6-12 months, >0-6 months vs. 1-2 yr; z0-6 months vs. 2-5 yr; y0-6 months vs. 5-10 yr; x0-6 months vs. 10-16 yr; w6-12 months vs. 1-2 yr; v6-12 months vs. 2-5 yr; u6-12 months vs. 5-10 yr; t6-12 months vs. 10-16 yr; s1-2 yr vs. 2-5 yr; r1-2 yr vs. 5-10 yr; q1-2 yr vs. 10-16 yr; p2-5 yr vs. 5-10 yr; o2-5 yr vs. 10-16 yr; n5-10 yr vs. 10-16 yr; aPer cent of leucocyte; bPer cent of peripheral lymphocytes; cPer cent of Th cells; dPer cent of Tc cells; ePer cent of B cells; fPer cent of T cells; gPer cent of NK cells; hPer cent of CD3+CD4-CD8-gd-T cells. CM, central memory; EM, effector memory; TEMRA, terminally differentiated effector memory re-expressing CD45RA; DNT, double negative T; Tc, T cytotoxic; Th, T helper; NK, natural killer; gd, gamma delta; TCRgd, T cell receptor gd; HLADR: human leukocyte antigen DR

Stepwise gating strategy for lymphocytes, general lymphocyte subpopulation, T, B, NK and activated cell subpopulations. (A) FSC-H vs. FSC-A plot was used to remove doublets and cell debris. (B) Singlet cells were further plotted against SSC-A vs. FSC-A. (C) SSC-A vs. CD45 was used to gate lymphocytes, based on low forward/side scatter and bright CD45. (D) Density plot demonstrating NK cells (CD3- CD16/CD56+) and NKT cells (CD3+ CD16/CD56+). (E) T cells were gated using CD45 and CD3. (F-J) T cell populations were distinguished depending on CD4, CD8, CD27, CD45RA and TCRgd expression. (K-N) B cells were gated as CD19+CD3- and the subpopulations were distinguished depending on IgD, IgM and CD27 expression. (O-S) HLA-DR was used to access the activation status on DNTs, T, Tc, Th, NK cells respectively. The names written above the plot [name] represent the parent gate. NK, natural killer
Fig. 1
Stepwise gating strategy for lymphocytes, general lymphocyte subpopulation, T, B, NK and activated cell subpopulations. (A) FSC-H vs. FSC-A plot was used to remove doublets and cell debris. (B) Singlet cells were further plotted against SSC-A vs. FSC-A. (C) SSC-A vs. CD45 was used to gate lymphocytes, based on low forward/side scatter and bright CD45. (D) Density plot demonstrating NK cells (CD3- CD16/CD56+) and NKT cells (CD3+ CD16/CD56+). (E) T cells were gated using CD45 and CD3. (F-J) T cell populations were distinguished depending on CD4, CD8, CD27, CD45RA and TCRgd expression. (K-N) B cells were gated as CD19+CD3- and the subpopulations were distinguished depending on IgD, IgM and CD27 expression. (O-S) HLA-DR was used to access the activation status on DNTs, T, Tc, Th, NK cells respectively. The names written above the plot [name] represent the parent gate. NK, natural killer
Gating strategy for T cell and its subpopulation like Naïve, CM, EM, Terminally differentiated effector memory re-expressing CD45RA+ (TEMRA) and RTE cells. (A) FSC-H vs. FSC-A plot was used to remove doublets cell debris. (B) Singlet cells were further plotted against SSC-A vs FSC-A. (C) SSC-A vs. CD45 was used to gate lymphocytes, based on low forward /side scatter and bright CD45. (D) SSC-A vs. CD3 was used to identify T cells. (E) T cells were characterized as T helper cells/cytotoxic T cells based on the expression of CD4 and CD8. (F and I) Quadrant density plot representing naïve, central, effector memory and TEMRA sub population using CD62L and CD45RA on Th and Tc cells. (G, J, H and K) Recent thymic emigrants (RTE) were identified based on co-expression of CD31 and CD45RA and or CD62L on both Th and Tc cells. The names written above the plot (name) represent the parent gate. CM, Central memory; EM, effector memory; RTE, recent thymic emigrant
Fig. 2
Gating strategy for T cell and its subpopulation like Naïve, CM, EM, Terminally differentiated effector memory re-expressing CD45RA+ (TEMRA) and RTE cells. (A) FSC-H vs. FSC-A plot was used to remove doublets cell debris. (B) Singlet cells were further plotted against SSC-A vs FSC-A. (C) SSC-A vs. CD45 was used to gate lymphocytes, based on low forward /side scatter and bright CD45. (D) SSC-A vs. CD3 was used to identify T cells. (E) T cells were characterized as T helper cells/cytotoxic T cells based on the expression of CD4 and CD8. (F and I) Quadrant density plot representing naïve, central, effector memory and TEMRA sub population using CD62L and CD45RA on Th and Tc cells. (G, J, H and K) Recent thymic emigrants (RTE) were identified based on co-expression of CD31 and CD45RA and or CD62L on both Th and Tc cells. The names written above the plot (name) represent the parent gate. CM, Central memory; EM, effector memory; RTE, recent thymic emigrant
Age-related ranges for absolute lymphocyte subset counts. Flow cytometric analysis of 148 healthy individuals amongst seven different age groups. All values of this reference dataset are represented as box plots with median, p10, p25, p75 and p90 percentile. For the data visualization package ggplot2 for the statistical language, R was used. Cb, cord blood; yr, years, m, month
Fig. 3
Age-related ranges for absolute lymphocyte subset counts. Flow cytometric analysis of 148 healthy individuals amongst seven different age groups. All values of this reference dataset are represented as box plots with median, p10, p25, p75 and p90 percentile. For the data visualization package ggplot2 for the statistical language, R was used. Cb, cord blood; yr, years, m, month
Age-related ranges for the percentage of lymphocyte subset counts. Flow cytometric analysis of 148 healthy individuals amongst seven different age groups. All values of this reference dataset are represented as box plots with median, p10, p25, p75, and p90 percentile. For the data visualization package ggplot2 for the statistical language, R was used. Cb, cord blood; yr, years; m, month.
Fig. 4
Age-related ranges for the percentage of lymphocyte subset counts. Flow cytometric analysis of 148 healthy individuals amongst seven different age groups. All values of this reference dataset are represented as box plots with median, p10, p25, p75, and p90 percentile. For the data visualization package ggplot2 for the statistical language, R was used. Cb, cord blood; yr, years; m, month.

The presented data has unveiled noteworthy trends in the lymphocyte and T-lymphocyte profiles across age groups. During early infancy, there is a conspicuous elevation in the absolute counts of total lymphocytes and T-lymphocytes, which subsequently diminish with advancing age. Notably, the proportion of T cells while varying slightly with a median range spanning from 62 to 73 per cent showed a stable pattern over time. Furthermore, specific T cell subsets such as Th and Tc cells remained relatively constant, exhibiting medians within the range of 35 to 48 per cent for Th cells and 17.8 to 27 per cent for Tc cells.

Of particular interest was the observation regarding the CD4/CD8 ratio, which underwent a gradual decline with increasing age. Furthermore, the populations of naive T cells and recently thymic emigrants (RTE) along with Tc cells exhibit a progressive reduction with progressing age. In contrast, central memory and effector memory T cells increased in the later years of life. TEMRA (terminally differentiated effector memory RA+) on CD4 cells remained relatively low across various age groups; however, CD8 cells showed an increasing trend with age.

The relative frequency of T cell receptor gamma delta (TCRgd+) cells increased till 16 yr of age, whereas double-negative TCRgd+ T cells increased till 10 yr of age after which they declined. The TCRgd T-cells showed an overall decreasing pattern and double-negative TCRgd T-cells remained stable, showing a relative frequency of 0.68-1.85 per cent. T cell activation status as assessed by HLA-DR expression showed an increasing pattern up to one year following a gradual declines. CD45RA and HLA-DR co-expression accessed for double-negative T (DNT) TCRgd cells was found to be 3-7.6 per cent. DNT cells were relatively stable.

It was observed that absolute B-cell count and the percentage decrease with age. Naive B-cells showed the same pattern, while B memory and un-switched cells showed an increasing absolute count up to two years followed by a gradual decrease. IgM-only memory B cells remain very low. There is an increase in class-switched memory B cells with age. NK cell counts are relatively stable across the age groups.

Discussion

Advances in multicolour flow cytometry allow one to look at an array of immune parameters which are typically evaluated in different disease situations such as autoimmunity, immunodeficiency, malignancy and infectious diseases. For interpretation of results, although there are several studies reporting reference values for basic lymphocyte subsets in different populations globally4-7,14,16-19, a lack of paediatric age reference values for the extended lymphocyte subset is evident. To the best of our knowledge, there are no studies from India that give reference values for rare subsets for paediatric age groups such as naïve and memory T/B cell, RTE, activated T, activated NK cells, NKT cells, DNT cells, TCRgd+ T cells or HLADR and CD45RA co-expression on DNT cells.

In certain diseases, especially IEI, the basic lymphocyte subset may be normal, but individual subpopulations may be abnormal, and evaluation of such subsets is important. In this study such reference ranges have been utilized in interpreting immunological parameters in patients with IEI, especially severe combined immunodeficiency (SCID), combined immunodeficiency (CID), predominant antibody deficiencies (PADs) and primary immune regulatory disorders20-24.

To differentiate true lymphopenia from transient lymphopenia, i.e. if T-cells are low but naive T-cells counts are normal, it is suggestive of transient lymphopenia, whereas if both are on the lower side, it suggests SCID25. RTE plays a vital role in autoimmune diseases like rheumatoid factor-negative polyarticular juvenile idiopathic arthritis and in adults with systemic lupus erythematosus, type I diabetes and psoriasis16. CD8 RTE plays a major role in chronic viral diseases, its decrease has been associated with SCID and Ommens syndrome26. HLA-DR and CD45RA co-expression on DNT cells is reported to be elevated in autoimmune lymphoproliferative syndrome, signal transducer and activator of transcription 3-gain-of-function, and CTLA4 deficient patients27.

Patients with PADs such as common variable immunodeficiency and CID-like hyper IgM can have normal B-cell count but reduced memory and class switch cells. DOCK-8 deficient patients show an increase in naïve and a decrease in memory B cells28. IEIs like PI3KCD-activated p110 δ syndrome can have B and T cell abnormalities such as low pre-GC memory B cells, class-switched memory B cells and skewing of CD4+ with CD8+ T cells towards terminally differentiated effector cells1. CD27 deficiency can be identified based on absent CD27 expression on naive T cells with no memory B cells.

We thus report pilot data for 34 immune parameters, both absolute as well as relative counts (Figs. 3 and 4). This preliminary study can be used as a pilot for future large scale multicentric study to determine the reference values that can help in making the diagnosis of several infectious and immunological diseases like IEI (

Supplemantary Fig. 2
) as well as monitoring the treatment outcome.

The lymphocyte subset reference ranges were compared among the American, Asian, European, African and Indian populations for available subsets1,6,7,14,16,18,29 (Supplementary Table III). The majority of T, B and NK cell subsets showed no significant difference across the different populations (Supplementary Table III.). T helper cells were higher than in the Cameroonian population, and T cytotoxic cells were higher than in the African and American populations, as reported previously7,14.

Supplementary Table III Comparison of reference values of absolute counts of lymphocyte subsets in children amongst different countries
Subset/country CB 0-6 m 6-12 m 1-2 yr 2-5 yr 5-10 yr 10-16 yr
Lymphocyte 3627 6013 6029 5210 4226 3108 3087
NIIH (present study) 2809-5917 3744-8637 3537-8294 3182-7410 3048-6752 2258-4781 2038-4113
Euroflow1 2040-5688 2443-9955 4821-8531 2356-13275 1620-6856 1827-4564 1238-4792
USA NA 5400 (3400-7600) 6300 (3900-9000) 5900 (3400-9000) 5500 (3600-8900) 3600 (2300-5400) 2700 (1900-3700) 2200 (1400-3300)
Italy6 NA 5740 (4054-7048) 5690 (3320-7006) 4685 (3873-6141) 3800 (2340-5028) 2500 (1662-3448) 2285 (1340-3173)
China male17 NA 5310 (3680-7340) 5890 (3730-8760) 4440 (2790-6350) 2940 (2280-3820) 2530 (2020-3610) 2440 (1780-3440)
China female17 NA 5120 (4020-6450) 5710 (3780-8110) 4390 (2980-5950) 3040 (2370-4290) 2650 (2020-3500) 2490 (1760-3000)
Netherland16 5400 (3100-9400) 6500 (3400-12200) 6300 (3200-12300) 4100 (1400-12100) 2700 (1400-5500) 2400 (1200-4700) 2400 (1400-4200)
T cell 2423 4321 3952 3642 2744 2300 2291
NIIH 1889-4764 2617-5380 2252-5788 2105-5460 2087-4899 1639-3388 1390-3008
India14,29 2402.38 (1725-3406) 3421 (952-8586) 4630 (1623-8159) 3801 (1480-6475) 3110 (1191-6692) 2347 (1191-4497) 1960 (1035-4493)
Euroflow1 1186-4113 1680-7754 3764-6289 1900-9345 852-5333 1352-3275 930-3477
USA7 NA 3930 (2500-5600) 3930 (1900-5900) 3550 (2100-6200) 2390 (1400-3700) 1820 (1200-2600) 1480 (1000-2200)
Italy6 NA 4040 (3180-5401) 3833 (2284-4776) 3133 (2542-4933) 2580 (1578-3707) 1793 (1239-2611) 1629 (954-2332
India19 2859 (3100-5200) 3631 (1767-5495) 2994 (1278-4710) 2506 (1222-3790) 2590 (1368-3812) NA NA
Cameroon18 2249 (430-2977) 3085 (2352-4776) 3120 (1123-4378) 3522 (2039-5024) 2639 (794-3307) 2299 (1159-3242) NA NA
China17 NA 3391 (1885-4954) 3625 (1571-7165) 2816 (1355-4921) 2028 (1254-3216) 1758 (1093-3013) 1649 (999-2607)
Netherland16 3100 (1400-6800) 4500 (2200-9200) 4400 (2400-8300) 2500 (700-8800) 1900 (850-4300) 1800 (770-4000) 1600 (850-3200)
Th cell 1637 2802 2274 2090 1463 1109 1168
NIIH 1060-3558 1336-3327 1207-4013 1154-3460 1001-2535 805-1855 659-1547
India14,29 1808 (1260-2440) 2156 (659-6132) 2852 (913-5680) 2271 (817-4893) 1821 (794-4323) 1266 (618-2555) 1080 (582-2045)
Euroflow1 952-3097 1273-5633 2093-4769 617-5959 516-3448 776-1815 576-1891
USA7 NA 2610 (1600-4000) 2850 (1800-4000) 2670 (1400-4300) 2160 (1300-3400) 1380 (700-2200) 980 (650-1500) 840 (530-1300)
Italy6 NA 3079 (2330-3617) 2492 (1523-3472) 1866 (1573-2949) 1448 (870-2144) 1030 (646-1515) 887 (610-1446)
Cameroon18 1552 (330-1995) 2001 (1642-3472) 2133 (759-3205) 2252 (1311-3273) 1667 (596-1949) 1289 (674-1721) NA NA
India19 1707 (2209-3205) 2932 (1516-4348) 2427 (1056-3799) 2029 (1113-2946) 1977 (839-3115) NA NA
China17 NA 2287 (1217-3422) 2318 (850-4658) 1472 (717-2798) 1001 (546-1768) 839 (496-1479) 781 (391-1421)
Netherland16 2200 (1000-4800) 3300 (1600-6500) 3000 (1300-7100) 1600 (400-7200) 1100 (500-2700) 1000 (400-2500) 900 (400-2100)
Tc cell 707 1010 1315 1185 1057 856 841
NIIH 451-1346 618-1778 548-1930 781-1692 562-1809 508-1257 471-1242
India14,29 721 (558-1064) 970 (159-3717) 1407 (455-3393) 1319 (549-2844) 1084 (315-2258) 913 (422-1878) 767 (405-2615)
Euroflow1 213-1138 354-2006 720-1271 364-2498 188-1805 366-1171 261-1189
USA7 NA 980 (560-1700) 1050 (590-1600) 1040 (500-1700) 1040 (620-2000) 840 (490-1300) 680 (370-1100) 530 (330-920)
Italy6 NA 1048 (712-1361) 976 (524-1583) 884 (656-1432) 804 (472-1107 595 (365-945) 518 (282-749)
Cameroon18 554 (140-1188) 790 (570-1714) 726 (298-1413) 995 (563-1796) 823 (194-1165) 775 (308-1249) NA NA
India19 836 (312-1360) 1544 (970-2118) 1133 (541-2807) 1269 (523-2015) 1373 (749-1997) NA NA
China17 NA 963 (436-1846) 1212 (472-2874) 1047 (397-2080) 765 (455-1430) 709 (396-1325) 699 (366-1091)
Netherland16 800 (200-2700) 1000 (300-3400) 1200 (400-4100) 700 (200-2800) 600 (200-1800) 600 (200-1700) 600 (300-1300)
Th Naïve cell 1445 2619 1797 1552 1057 825 644
NIIH 1001-3329 993-3086 758-2992 816-2509 711-1844 416-1462 325-1208
Euroflow1 920-2897 1092-5337 1748-4201 360-5273 276-2902 424-1393 264-1484
USA7 NA 2250 (1200-3600) 2230 (1300-3600) 2100 (1100-3600) 1640 (950-2800) 960 (420-1500) 560 (310-1000) 390 (210-750)
China male17 NA 1839 (1170-2595) 1802 (764-2972) 918 (472-1760) 595 (321-972) 407 (294-683) 410 (230-627)
China female17 NA 1908 (1433-2546) 1967 (1042-3160) 929 (530-1837) 633 (339-1037) 489 (299-857) 442 (276-654)
Netherland16 1800 (900-3900) 3100 (1600-6000) 2700 (1100-6400) 1300 (200-7500) 800 (300-2300) 700 (200-2500) 600 (200-1700)
Th Naïve cell (CD62L) 1503 2177 1811 1578 957 632 564
NIIH 944-3371 875-2896 793-3181 791-2812 627-1570 388-1268 285-995
Cameroon18 (CD62L) 1201 (693-1589) 1392 (798-2304) 1304 (453-2134) 1541 (763-2538) 708 (282-1559) 665 (395-1334) NA NA
Tc Naïve cell 624 869 773 757 790 537 414
NIIH 418-1206 434-1135 410-1223 437-1185 456-1293 306-844 244-829
Euroflow1 200-1010 330-1841 564-1040 222-2178 126-1130 175-730 94-986
USA7 NA 730 (380-1300) 740 (450-1200) 700 (330-1200) 760 (400-1400) 540 (260-850) 410 (200-650) 300 (170-560)
China male17 NA 800 (503-1276) 909 (535-1677) 653 (356-1095) 462 (297-730) 380 (245-657) 375 (231-568)
China female17 NA 741 (484-1009) 726 (461-1235) 589 (295-971) 447 (293-768) 387 (232-665) 328 (210-560)
Netherland16 360 (23-1300) 690 (290-1650) 580 (140-2460) 310 (30-3100) 240 (53-1100) 240 (42-1300) 220 (78-640)
Tc Naïve cell (CD62L) 656 823 754 821 791 633.5 470
NIIH 419-1146 369-1169 374-1307 506-1243 405-1233 301-991 230-653
Cameroon18 (CD62L) 457 (91-826) 545 (272-809) 404 (219-757) 524 (236-1042) 330 (120-555) 384 (156-641) NA NA
B cell 628 1912 1405 1124 815 440 556
NIIH 255-972 240-2636 715-2531 718-2007 510-1662 286-924 273-813
India14,29 518 (366-697) 1654 (351-5946) 1915 (523-3799) 1484 (246-4139) 1187 (362-2754) 653 (295-1650) 507 (115-1117)
Euroflow1 347-1053 470-4327 896-2316 353-2300 232-1637 157-725 173-1194
USA7 NA 1550 (430-3000) 1520 (610-2600) 1310 (720-2600) 750 (390-1400) 480 (270-860) 300 (110-570)
Cameroon18 552 (85-853) 1525 (513-3748) 1940 (696-3370) 1858 (662-2870) 1526 (487-2066) 965 (432-1691) NA NA
India19 1175.7 (61-2447.5) 1537.9 (860-2215.8) 746.3 (25-1809) 719.3 (88-1576.8) 776.9 (56-1697.3) NA NA
China7 NA 1185 (113-2317) 1254 (522-2175) 839 (359-2037) 443 (231-910) 347 (154-685) 312 (141-534)
Netherlands16 540 (140-2000) 1100 (520-2300) 940 (110-7700) 760 (160-3700) 490 (180-1300) 290 (100-800) 300 (120-740)
Italy6 NA 1032 (315-1383) 1123 (776-2238) 1152 (733-1338) 730 (434-1274) 403 (276-640) 321 (173-685)
Netherland16 NA 1623 (961-3679) 1717 (571-3680) 1157 (686-1732) 593 (278-1022) 338 (116-555) 284 (119-578)
NK cell 250 338 297 342 325 258 238
NIIH 69-1412 220-779 84-1237 144-565 130-636 90-679 110-437
India14,29 760 (450-1059) 489 (114-1624) 433 (105-1088) 368 (114-1201) 335 (131-1163) 362 (124-1005) 334 (78-774)
Euroflow1 200-1305 167-1359 237-1146 104-2436 138-1759 106-1348 109-1021
USA7 NA 420 (170-1100) 400 (160-950) 360 (180-920) 300 (130-720) 230 (100-480) 190 (70-480)
Italy6 NA 408 (208-1700) 381 (230-801) 296 (186-724) 299 (155-565) 262 (120-483) 230 (87-504)
Cameroon18 496 (135-969) 546 (262-1030) 450 (140-1229) 504 (109-831) 397 (151-848) 333 (133-1042) NA NA
China17 NA 446 (168-1156) 505 (179-1522) 499 (166-1669) 418 (181-1000) 394 (119-1077) 424 (121-1064)
Netherlands16 120 (500-3100) 440 (97-1990) 500 (71-3500) 470 (55-4000) 180 (61-510) 200 (70-590) 330 (92-1200)
Activated Th 4/DR 7 45 53 35 27 31 39
NIIH 2-24 32-120 22-76 16-117 17-97 17-64 13-67
Cameroon18 21 (9-82) 75 (56-164) 74 (29-155) 77 (45-209) 70 (29-127) 65 (34-122) NA NA
USA7 NA 150 (60-280) 120 (50-260) 130 (70-280) 90 (50-180) 70 (40-120) 60 (30-100)
Activated Tc 8/DR 3 142 101 108 41.5 50 50
NIIH 1-8 13-295 14-263 21-209 14-195 20-124 9-139
Cameroon18 6 (2-25) 34 (8-287) 45 (13-324) 102 (30-342) 81 (21-216) 77 (39-307) NA NA
USA7 NA 80 (30-170) 90 (40-290) 180 (60-600) 140 (70-420) 90 (40-270) 70 (30-180)
TCRgd+T cell 68 191 246 206 241 189 189
NIIH 26-174 119-545 73-558 135-340 133-406 97-390 64-353
Euroflow1 18-121 25-435 128-335 86-537 44-784 66-416 56-332
Netherlands16 87 (30-250) 170 (56-510) 210 (70-630) 160 (41-640) 160 (27-960) 160 (27-960) 150 (39-540)
China male17 97 (51-240) 141 (92-279) 238 (128-436) 267 (114-539) 233 (124-410) 210 (124-388) 198 (81-343)
China female17 139 (71-356) 187 (94-301) 205 (143-409) 283 (128-520) 243 (134-428) 234 (121-462) 176 (85-358)
DNT gd-/ab+T 26 51 59 88 85 45 40
NIIH 14-56 17-149 30-105 42-137 48-125 30-90 26-65
Euroflow1 0-37 9-66 15-73 20-141 3-104 13-80 8-53
Netherlands16 28 (10-79) 22 (5.5-140) 33 (11-100) 48 (13-170) 47 (16-140) 32 (1-100) 27 (9-78)
China male17 20 (11-26) 18 (11-45) 29 (16-58) 27 (9-57) 23 (4-55) 26 (13-48) 23 (12-37)
China female17 17 (6-35) 23 (13-38) 37 (19-72) 31 (16-58) 26 (4-49) 23 (12-41) 22 (13-44)
Th RTE 1297 1905 1625 1375 806 570 459
NIIH 842-2911 766-2563 593-2977 701-2388 522-1456 342-1126 227-860
Spain3 NA 1440 (600-2700) 1440 (600-2700) 1440 (600-2700) 800 (600-1600) 590 (300-1000) 520 (300-700)
Netherlands16 1700 (710-4200) 2700 (1400-5200) 2200 (800-6200) 1100 (170-7400) 710 (190-2600) 590 (200-1700) 480 (150-1500)

Data of absolute numbers represented as median and (10th to 90th) or (5-95th) percentiles. Data sources: NIIH-this study, Euroflow1; Netherlands16; China17; Spain3; Italy6; Cameroon18; India Thakar et al.14; India Prabhu et al.29; India Narula et al.19; Thakur et al: from 0 to 16 yr; Prabhu et al: CB. NA, not available; NIIH, National Institute of Immuno Haematology; CB, cord blood, RTE, recent thymic emigrants; DNT, double negative T; gd, gamma delta; TCRgd, T cell receptor gd; Tc, T cytotoxic; Th, T helper; HLADR, human leukocyte antigen DR

Due to the relative lymphocytosis in healthy infants, the corresponding Th and Tc cell counts were elevated for a year and then declined with age. Naïve T-cells can be identified using a combination of various markers such as CCR7, CD62L, CD27, CD28 and CD45RA30. We used a combination of CD62L and CD27 with CD45RA. Using unpaired t test, we found no significant difference between naïve helper and naïve cytotoxic populations gated on CD27 and CD62L, but memory and effector group sub-populations did show a difference (Supplementary Table IV). Thus, naïve T cells can be identified using any of the markers along with CD45RA. Our data are consistent with known effects of development, including lower naïve Th and Tc cells and accumulating T cell subsets with a memory phenotype3,16. It reflects a gradual decline in the naïve T cells due to ageing and thymic involution and also the increased immunological memory due to exposure to environmental antigens 31. In the absence of newborn screening for SCID in India, flow cytometric assessment of naïve T cells in suspected cases provides a mechanism for prompt diagnosis while awaiting molecular confirmation.

Supplementary Table IV Comparison between T helper and T cytotoxic subsets using CD62L versus CD27 as gating marker as assessed by unpaired t-test
t test CD4 CD8
Naive CM EM TEMRA Naive CM EM TEMRA
CB 0.788 0.1222 <0.0001 <0.0001 0.9941 0.0054 0.0064 0.0084
0-6 months 0.4916 0.6512 0.052 0.2518 0.8375 0.7936 0.625 0.9072
6-12 months 0.6982 0.1677 0.0009 0.0387 0.9156 0.06 0.2484 0.7008
1-2 yr 0.8901 0.1166 <0.0001 0.0619 0.814 0.0517 0.0027 0.7298
2-5 yr 0.3292 0.0009 <0.0001 0.0007 0.8584 0.0978 0.0088 0.9822
5-10 yr 0.1465 0.0051 <0.0001 0.0236 0.3236 0.0854 0.0005 0.0037
10-16 yr 0.2209 0.0783 <0.0001 0.6732 0.9839 0.0848 0.0337 0.4895

The boxes highlighted in yellow represents non-significant differences. CM, central memory; EM, effector memory; TEMRA, terminally differentiated effector memory re-expressing CD45RA; CB, cord blood

TCRgd+ T cell relative percentages reportedly increase with age, as seen in other populations. The absolute counts have been shown to increase up to 10 years of age followed by a decline, as seen in the Chinese population. The median cell count was found to be higher compared to the European population but was similar to that of the Chinese, suggesting an increased exposure to pathogens in the Asian population compared to Europeans16,17.

Naive B cells have been shown to predominate in the peripheral B cell pool during infancy, and the fraction of class-switched and non-switched memory B cells increases gradually with age. B memory cell percentage rises until 10 yr of age followed by a marginal decrease similar to that of the European population32,33. The absolute count reportedly increases for two years after which there is a decline32.

NK cell subsets were relatively stable overall. Previous studies have shown that diseases like XLP, SAP deficiency, have low NKT cell28, whereas activated HLA-DR is increased in severe COVID -19 patients34. In our study we present the range for NKT cells and activated HLA-DR expression ranges for healthy children which can be used in such diseases.

The present study has a few limitations; the most important being the low sample size in the younger age group and lack of consideration of region-wise variability as the study was single centric. We relied mostly on pre-surgical samples of benign procedures for the younger age group because it was difficult to get samples from these groups due to hesitation from parents to consent. A recent study from India and several international publications have shown no significant difference between males and females; thus, we did not compare our data separately5,14,16,17. Furthermore, we could not assess few T cells subsets such as Tregs, T follicular helper and Th1, Th2, Th17 and B cell subsets such as plasmablasts and transitional B cells.

Overall, this study provides preliminary data that justify the need for future large-scale multi-centric studies to generate a reference range for interpreting extended immunophenotyping profiles in the paediatric age group, making it possible for clinicians to assess the immunological status in IEI, infectious and autoimmune diseases.

Financial support and sponsorship

This study received funding from the Indian Council of Medical Research, New Delhi (F NO.61/02/2012/IMM-BMS).

Conflicts of interest

None.

Supplementary Fig. 1

Supplementary Fig. 1 Consort diagram of inclusion of participants.

Supplementary Fig. 2

Supplementary Fig. 2 Application of age-matched ranges in diagnosing clinically suspicious IEI. IEI, inborn errors of immunity

Acknowledgment:

Authors acknowledge Shri Govind, BJ Wadia hospital for assitance in sample collection, Shrimati Sonal Narkar and Kamble, RM Bhatt High School for allowing us to conduct a school camp for sample collection and, Drs Jahnavi Aluri and Snehal Shabrish for their scientific inputs throughout the study.

References

  1. , , , , , , . The EuroFlow PID orientation tube for flow cytometric diagnostic screening of primary immunodeficiencies of the lymphoid system. Front Immunol. 2019;10:246.
    [Google Scholar]
  2. , , , , , , . Human inborn errors of immunity:2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020;40:24-64.
    [Google Scholar]
  3. , , , , , , . Extended immunophenotyping reference values in a healthy pediatric population. Cytometry B Clin Cytom. 2019;96:223-33.
    [Google Scholar]
  4. , , , . Age-related lymphocyte subset changes in the peripheral blood of healthy children –A meta-study. Transfus Med Hemother. 2007;34:176-81.
    [Google Scholar]
  5. , , , , , , . Reference ranges of lymphocyte subsets balanced for age and gender from a population of healthy adults in Chongqing District of China. Cytometry B Clin Cytom. 2016;90:538-42.
    [Google Scholar]
  6. , , , , , , . Lymphocytes subsets reference values in childhood. Cytometry A. 2015;87:81-5.
    [Google Scholar]
  7. , , , , , , . Lymphocyte subsets in healthy children from birth through 18 years of age: The Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol. 2003;112:973-80.
    [Google Scholar]
  8. , , , , , , . Reference values for a panel of cytokinergic and regulatory lymphocyte subpopulations. Immune Netw. 2016;16:344-57.
    [Google Scholar]
  9. , , , . Diagnostic approach to primary immunodeficiency disorders. Indian Pediatr. 2013;50:579-86.
    [Google Scholar]
  10. , , , , . Primary immunodeficiency disorders in India –A situational review. Front Immunol. 2017;8:714.
    [Google Scholar]
  11. , , , , , . Age-related changes in blood lymphocyte subsets of south Indian children. Natl Med J India. 2003;16:249-52.
    [Google Scholar]
  12. , , , , , , . Establishment of reference CD4+T cell values for adult Indian population. AIDS Res Ther. 2011;8:35.
    [Google Scholar]
  13. , , , , , , . Reference ranges for lymphocyte subsets in adults from western India: Influence of sex, age and method of enumeration. Indian J Med Sci. 2008;62:397-406.
    [Google Scholar]
  14. , , , , , , . Reference ranges of different lymphocyte subsets in Indian children: A multi-centric study. Indian Pediatr. 2021;58:424-9.
    [Google Scholar]
  15. , . Dacie and Lewis practical haematology: Ninth edition. Pathology. 2002;34:485.
    [Google Scholar]
  16. , , , , , , . Paediatric reference values for the peripheral T cell compartment. Scand J Immunol. 2012;75:436-44.
    [Google Scholar]
  17. , , , , , , . Reference values for peripheral blood lymphocyte subsets of healthy children in China. J Allergy Clin Immunol. 2018;142:970-3.e8.
    [Google Scholar]
  18. , , , , , , . Reference values of lymphocyte subsets in healthy, HIV-negative children in Cameroon. Clin Vaccine Immunol. 2011;18:790-5.
    [Google Scholar]
  19. , , , , . Age-related reference intervals for immunoglobulin levels and lymphocyte subsets in Indian children. Indian J Pathol Microbiol. 2017;60:360-4.
    [Google Scholar]
  20. , , , , , , . Clinical, immunological, and molecular findings in 57 patients with severe combined immunodeficiency (SCID) from India. Front Immunol. 2019;10:23.
    [Google Scholar]
  21. , , , , , , . Application of flow cytometry in primary immunodeficiencies: Experience from India. Front Immunol. 2019;10:1248.
    [Google Scholar]
  22. , , , , , , . Clinical, immunological and genomic characteristics of children with X-linked agammaglobulinemia from Kerala, South India. Hum Immunol. 2022;83:335-45.
    [Google Scholar]
  23. , , , , , , . XMEN saved by magnesium. Scand J Immunol. 2022;95:e13154.
    [Google Scholar]
  24. , , , , , , . CD8+T cells exhibit an exhausted phenotype in hemophagocytic lymphohistiocytosis. J Clin Immunol. 2021;41:1794-803.
    [Google Scholar]
  25. , , , , , , . Lymphopenia and severe combined immunodeficiency (SCID) –Think before you ink. Indian J Pediatr. 2019;86:584-9.
    [Google Scholar]
  26. , , , , , , . EuroFlow standardized approach to diagnostic immunopheneotyping of severe PID in newborns and young children. Front Immunol. 2020;11:371.
    [Google Scholar]
  27. , , , , , , . Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome. Blood. 2016;128:227-38.
    [Google Scholar]
  28. , , . Flow cytometric-based analysis of defects in lymphocyte differentiation and function due to inborn errors of immunity. Front Immunol. 2019;10:2108.
    [Google Scholar]
  29. , , , , , , . Comparison of human neonatal and adult blood leukocyte subset composition phenotypes. PLoS One. 2016;11:e0162242.
    [Google Scholar]
  30. , , , , , , . Guidelines for the use of flow cytometry and cell sorting in immunological studies. Eur J Immunol. 2017;47:1584-797.
    [Google Scholar]
  31. , , , , , , . Establishment of normative ranges of the healthy human immune system with comprehensive polychromatic flow cytometry profiling. PLoS One. 2019;14:e0225512.
    [Google Scholar]
  32. , , , , , , . B cell subsets in healthy children: Reference values for evaluation of B cell maturation process in peripheral blood. Cytometry B Clin Cytom. 2010;78:372-81.
    [Google Scholar]
  33. , , , , , , . B-cell subpopulations in children: National reference values. Immun Inflamm Dis. 2014;2:131-40.
    [Google Scholar]
  34. , , , , , , . Natural killer cell immunotypes related to COVID-19 disease severity. Sci Immunol. 2020;5:eabd6832.
    [Google Scholar]
Show Sections
Scroll to Top